Acer Therapeutics Closes $4.1 Million Series A Financing, Forms Board of Directors and Advances Lead Development Programs. CAMBRIDGE, MA, July 1, 2015 - Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant...

Acer Therapeutics Appoints Benjamin Dewees as Vice President, Regulatory Affairs and Manufacturing Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Benjamin Dewees as Vice...

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-002 for the Potential Treatment of Vascular Ehlers-Danlos Syndrome In January 2015, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with...

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-001 for the Potential Treatment of Maple Syrup Urine Disease In August 2014, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant...

Acer Therapeutics Licenses Exclusive Worldwide Rights from Baylor College of Medicine for Development of Sodium Phenylbutyrate for Maple Syrup Urine Disease In April 2014, Acer Therapeutics Inc. entered into an exclusive worldwide license agreement with Baylor College...

Acer Therapeutics Closes $4.1 Million Series A Financing, Forms Board of Directors and Advances Lead Development Programs. CAMBRIDGE, MA, July 1, 2015 - Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant...

Acer Therapeutics Appoints Benjamin Dewees as Vice President, Regulatory Affairs and Manufacturing Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Benjamin Dewees as Vice...

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-002 for the Potential Treatment of Vascular Ehlers-Danlos Syndrome In January 2015, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with...

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-001 for the Potential Treatment of Maple Syrup Urine Disease In August 2014, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant...

Acer Therapeutics Licenses Exclusive Worldwide Rights from Baylor College of Medicine for Development of Sodium Phenylbutyrate for Maple Syrup Urine Disease In April 2014, Acer Therapeutics Inc. entered into an exclusive worldwide license agreement with Baylor College...